From the Guidelines
Zepbound (ozanimod) is not contraindicated in Barrett's esophagus, but patients should be monitored for potential worsening of gastroesophageal reflux symptoms. The most recent guidance from the National Institute for Health and Care Excellence (NICE) on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma, published in 2024 1, does not mention ozanimod as a contraindication. However, it is essential to consider the potential effects of ozanimod on gastroesophageal reflux symptoms, as reflux is a risk factor for Barrett's progression.
Key considerations for patients with Barrett's esophagus taking Zepbound (ozanimod) include:
- Monitoring for worsening gastroesophageal reflux symptoms
- Potential exacerbation of discomfort due to common side effects such as nausea, vomiting, and gastrointestinal distress
- Possible adjustment of medication dosage or recommendation of additional acid suppression therapy if reflux symptoms worsen
It is crucial for patients with Barrett's esophagus to discuss their treatment plan with their healthcare provider, including the potential risks and benefits of taking Zepbound (ozanimod) 1. The healthcare provider can help determine the best course of treatment and monitor the patient's condition accordingly.
From the Research
Zepbound (Ozanimod) and Barrett's Esophagus
There is no direct evidence in the provided studies regarding the contraindication of Zepbound (ozanimod) in Barrett's esophagus.
- The studies focus on the characteristics, risk factors, management, and chemoprevention of Barrett's esophagus 2, 3, 4, 5, 6.
- They discuss the use of proton pump inhibitors, statins, nonsteroidal anti-inflammatory drugs, and aspirin in the management and potential chemoprevention of Barrett's esophagus and esophageal adenocarcinoma 2, 3, 4, 5.
- However, none of the studies mention Zepbound (ozanimod) or its relationship with Barrett's esophagus.
Management and Chemoprevention of Barrett's Esophagus
The management of Barrett's esophagus primarily consists of acid-suppressive medications and surveillance endoscopy 2, 3.
- Proton pump inhibitors are recommended as first-line therapy for controlling reflux symptoms, and their role in chemoprevention is being explored 2, 3, 4, 5.
- Endoscopic therapy, including resection and ablation, is effective in treating high-grade dysplasia and early cancer in patients with Barrett's esophagus 2, 6.
Conclusion Not Provided as Per Request
As per the request, no conclusion will be drawn, and the response will only provide information based on the available evidence.